Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cisplatin + 5-fluorouracil with or without panitumumab in advanced or metastatic esophageal squamous cell carcinoma
2010-020606-15Phase 3Terminated
- Sponsor
- AIO-Studien
- Start
- Dec 2011
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of panitumumab in Esophageal Squamous Cell Carcinoma (ESCC) and esophageal cancer (2 arms), sponsored by AIO-Studien. Primary endpoint: Overall survival. Started Dec 2011; status: terminated.
02
Drugs
panitumumab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)esophageal cancer
Beyond the preview
Go deeper on 2010-020606-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-020606-15.